Overview

A Study of TeriQ Patch in Healthy Adult Female Participants

Status:
COMPLETED
Trial end date:
2024-12-30
Target enrollment:
Participant gender:
Summary
This will be a single center, open-label, active-controlled, 3-way, incomplete block, crossover, randomized, and single escalating dose study.
Phase:
PHASE1
Details
Lead Sponsor:
QuadMedicine
Treatments:
Drug Evaluation